Effects of probiotic on intestinal mucosa of patients with ulcerative colitis

Cui, Hao; Chen, Cun-Long; Wang, Jide; Yang, Yujie; Cun, Yong; Wu, Ji‐Wei; Yu-hu, Liu; Dan, Han-Lei; Jian, Yan-Ting; Chen, Xueqing

doi:10.3748/wjg.v10.i10.1521

Cited by 184 publications

(120 citation statements)

References 31 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Lactobacilli and Bifidobacteria are natural components of the colonic microbiota, and as probiotic agents, they have been tested in the prevention and treatment of IBD (6,7). A strain of Lactobacillus casei, DN-114 001, has been shown to decrease the secretion of TNF-␣ from the inflammed ileum of Crohn's disease patients (8,9).…”

mentioning

confidence: 99%

Anti-Inflammatory Effect of Lactobacillus casei on Shigella-Infected Human Intestinal Epithelial Cells

Tien

Girardin

Regnault

et al. 2006

The Journal of Immunology

277

113

View full text Add to dashboard Cite

Shigella invades the human intestinal mucosa, thus causing bacillary dysentery, an acute recto-colitis responsible for lethal complications, mostly in infants and toddlers. Conversely, commensal bacteria live in a mutualistic relationship with the intestinal mucosa that is characterized by homeostatic control of innate responses, thereby contributing to tolerance to the flora. Cross-talk established between commensals and the intestinal epithelium mediate this active process, the mechanisms of which remain largely uncharacterized. Probiotics such as Lactobacillus casei belong to a subclass of these commensals that modulate mucosal innate responses and possibly display anti-inflammatory properties. We analyzed whether L. casei could attenuate the pro-inflammatory signaling induced by Shigella flexneri after invasion of the epithelial lining. Cultured epithelial cells were infected with L. casei, followed by a challenge with S. flexneri. Using macroarray DNA chips, we observed that L. casei down-regulated the transcription of a number of genes encoding pro-inflammatory effectors such as cytokines and chemokines and adherence molecules induced by invasive S. flexneri. This resulted in an anti-inflammatory effect that appeared mediated by the inhibition of the NF-κB pathway, particularly through stabilization of I-κBα. In a time-course experiment using GeneChip hybridization analysis, the expression of many genes involved in ubiquitination and proteasome processes were modulated during L. casei treatment. Thus, L. casei has developed a sophisticated means to maintain intestinal homeostasis through a process that involves manipulation of the ubiquitin/proteasome pathway upstream of I-κBα.

show abstract

mentioning

confidence: 99%

Anti-Inflammatory Effect of Lactobacillus casei on Shigella-Infected Human Intestinal Epithelial Cells

Tien

Girardin

Regnault

et al. 2006

The Journal of Immunology

277

113

View full text Add to dashboard Cite

show abstract

“…Gut-derived products may also play a role in increasing the systemic immune inflammatory response. Several observations, both on humans and animal models, emphasized the importance of bacterial flora in inflammatory bowel disease pathogenesis, justifying the current interest towards emerging antibiotic and probiotic therapies aimed at the manipulation of enteral flora 20 Human studies suggest beneficial bacteria have a positive effect in colitic patients. Probiotics may promote a positive immune response and concluded it may have the potential to promote and fortify the gut immunological barrier 21 .…”

Section: Discussionmentioning

confidence: 99%

Effects of budesonide and probiotics enemas on the colonic mucosa of rats with experimental colitis

et al. 2007

View full text Add to dashboard Cite

PURPOSE: To investigate the effect of enemas containing probiotics and budesonide on the colonic mucosa in experimental colitis. METHODS: Fifty male Wistar rats with experimental colitis induced by 10% acetic acid enema were randomized to five groups (10 rats each) according to the treatment: group 1 - saline solution, group 2 - budesonide (0.75 mg/kg/day), group 3 - probiotics (1mg/day), group 4 - probiotics plus budesonide, and group 5 - control, with not-treated rats. The following variables were studied: body weight, macroscopic and microscopic score of the colonic mucosa, and DNA content of the mucosa. RESULTS: All animals lost weight between the beginning and the end of the experiment (280+ 16 mg versus 249+21 mg, p< 0.001). There was no significant difference among the groups in relation to both the macroscopic and histological score. The budesonide + probiotic group showed higher DNA content than control group (1.24+ 0.15 versus 0.92+ 0.30 mg/100mg of tissue, p=0.01). CONCLUSION: Budesonide in addition to probiotics enhance the mucosal trophism in experimental colitis.

show abstract

“…The use of BiFico (oral capsules of live enterococci, bifidobacteria, and lactobacilli) in combination with sulphasalazine and glucocorticoid exerts some beneficial effects in preventing the relapse of Uc (ref. 33 ). The administration of BiFico plus sulphasalazine and glucocorticoid to Uc patients enlarged the number of bifidobacteria and lactobacilli and reduced the number of enterococci, bacteroides, and bifidobacteria present in the faeces compared with the control group.…”

Section: Discussionmentioning

confidence: 99%

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Palumbo¹,

Romeo²,

Gammazza³

et al. 2016

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aim.Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

show abstract

Effects of probiotic on intestinal mucosa of patients with ulcerative colitis

Cited by 184 publications

References 31 publications

Anti-Inflammatory Effect of Lactobacillus casei on Shigella-Infected Human Intestinal Epithelial Cells

Anti-Inflammatory Effect of Lactobacillus casei on Shigella-Infected Human Intestinal Epithelial Cells

Effects of budesonide and probiotics enemas on the colonic mucosa of rats with experimental colitis

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Contact Info

Product

Resources

About